Publicaciones en las que colabora con Julia del Amo Valero (19)

2021

  1. Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients with Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE

    Clinical Infectious Diseases, Vol. 73, Núm. 2, pp. 195-202

2020

  1. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2018

  1. Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation

    Journal of the International AIDS Society, Vol. 21, Núm. 11

  2. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  3. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

  4. Role of HIV in the desire of procreation and motherhood in women living with HIV in Spain: A qualitative approach

    BMC Women's Health, Vol. 18, Núm. 1

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. Kaposi sarcoma risk in HIV-infected children and adolescents on combination antiretroviral therapy from sub-Saharan Africa, Europe, and Asia

    Clinical Infectious Diseases, Vol. 63, Núm. 9, pp. 1245-1253

  3. Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy

    HIV Medicine, Vol. 17, Núm. 9, pp. 653-661

2014

  1. Delayed HIV diagnosis and initiation of antiretroviral therapy: Inequalities by educational level, COHERE in EuroCoord

    AIDS, Vol. 28, Núm. 15, pp. 2297-2306

2013

  1. Predictors of CD4+ T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes

    Journal of Infectious Diseases, Vol. 207, Núm. 5, pp. 759-767

  2. Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

    PLoS Medicine, Vol. 10, Núm. 9

2012

  1. CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: A longitudinal cohort study from COHERE

    PLoS Medicine, Vol. 9, Núm. 3

  2. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: A cohort study

    The Lancet Infectious Diseases, Vol. 12, Núm. 2, pp. 119-127

2011

  1. Risk of triple-class virological failure in children with HIV: A retrospective cohort study

    The Lancet, Vol. 377, Núm. 9777, pp. 1580-1587

2010

  1. Is it safe to discontinue primary pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 Cell Count <200 Cells/μL?

    Clinical Infectious Diseases, Vol. 51, Núm. 5, pp. 611-619

2009

  1. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy

    AIDS, Vol. 23, Núm. 15, pp. 2029-2037

2008

  1. Response to combination antiretroviral therapy: Variation by age

    AIDS, Vol. 22, Núm. 12, pp. 1463-1473